logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Dec 2019
Acasti Pharma, Inc.
Top line results from phase III trial to evaluate safety and efficacy of CaPre (TRILOGY 1)
Severe hypertriglyceridemia
Dec 2019
Apellis Pharmaceuticals, Inc.
Top-line data from phase III trial comparing APL-2 against Soliris(PEGASUS)
Paroxysmal nocturnal hemoglobinuria
Q4 2019
Prothena Corporation plc
Preliminary data from phase I study of PRX004
hATTR amyloidosis
Q4 2019
Protagonist Therapeutics, Inc
Initial results from phase II study of PTG-300 (TRANSCEND)
Transfusion-dependent as well as non-transfusion dependent beta-thalassemia
Q4 2019
Mereo BioPharma Group plc
12-month data from open-label arm of its phase 2b dose-ranging study of Setrusumab (BPS-804) (ASTEROID)
Type I, III or IV osteogenesis imperfecta in adults
Q4 2019
Autolus Therapeutics plc
Interim data from phase I trial of AUTO3
Diffuse large B-cell lymphoma (DLBCL)
Q4 2019
Paratek Pharmaceuticals, Inc.
Topline data from phase II studies of NUZYRA
Urinary tract infections
Q4 2019
Akari Therapeutics Plc
Data from phase II trial of Nomacopan
Mild-to-moderate bullous pemphigoid
Early Q4 2019
Nabriva Therapeutics
Resubmission of NDA for CONTEPO
cUTI incl acute pyelonephriti
Q4 2019
Ardelyx, Inc
Results from a phase III clinical trial of Tenapanor as a monotherapy treatment (PHREEDOM)
Hyperphosphatemia in patients with end-stage renal disease
Q4 2019
Oncternal Therapeutics Inc.
Additional data from Phase 1/2 study of Cirmtuzumab in combination with Ibrutinib
Chronic lymphocytic leukemia
Q4 2019
Oncternal Therapeutics Inc.
Additional data from Phase 1/2 study of Cirmtuzumab in combination with Ibrutinib
Mantle cell lymphoma
Q4 2019
Oncternal Therapeutics Inc.
Data from Phase 1 study of Cirmtuzumab in combination with Paclitaxel
Breast cancer
Q4 2019
Oncternal Therapeutics Inc.
Data from Phase 1 study of TK216
Ewing sarcoma
Oct 2019
ABIVAX SA
ABVX.PA
12-month data from phase IIa maintenance study of ABX-464 (ABX464-102)
Moderate to severe ulcerative colitis
Q4 2019
Eidos Therapeutics, Inc.
Data from open-label extension of a phase II clinical trial of AG10
Transthyretin amyloid cardiomyopathy (ATTR-CM)
Q4 2019
Syros Pharmaceuticals
Initial data from phase I trial of SY-1365 as single agent
Ovarian cancer
Q4 2019
Syros Pharmaceuticals
Initial data from phase I trial of SY-1365 in combination with standard-of-care therapies
Ovarian cancer
Q4 2019
Forty Seven, Inc.
Data from Phase 1b trial of 5F9 in combination with avelumab
Ovarian cancer
Q4 2019
Sesen Bio Inc
Submission of BLA for Vicinium
High-grade non-muscle invasive bladder cancer
Q4 2019
Achillion Pharmaceuticals Inc.
Submission of IND application for ACH-5228
Multiple diseases
Q4 2019
Regeneron Pharmaceuticals
Filing of sBLA for Dupixent
Severe atopic dermatitis in children
Q4 2019
Sanofi
Filing of sBLA for Dupixent
Severe atopic dermatitis in children
Q4 2019
Ascendis Pharma A/S
Top-line results from phase II study of TransCon PTH (PaTH Forward)
Hypoparathyroidism in adults
Q4 2019
ChemoCentryx Inc.
Top-line data from phase III study of Avacopan (ADVOCATE)
ANCA-associated vasculitis